Every Form 4 that RAPT Therapeutics, Inc. (RAPT) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow RAPT and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full RAPT filings page.
RAPT Therapeutics director Lori Lyons-Williams reported the cash-out of equity awards tied to the company’s acquisition by GSK. On March 3, 2026, multiple director stock options and 4,956 common shares were disposed of pursuant to a tender offer and merger at $58.00 per share, with RSUs and options cancelled and converted into cash under the Merger Agreement.
RAPT Therapeutics director Mary Ann Gray reported dispositions of stock options and shares tied to the company’s acquisition by a GlaxoSmithKline affiliate. On March 3, 2026, a GlaxoSmithKline LLC subsidiary completed a tender offer and merger, acquiring all RAPT common stock for $58.00 per share in cash.
Under the merger agreement, all outstanding restricted stock units were cancelled and converted into the right to receive cash based on the $58.00 offer price. Director stock options were accelerated and, if in the money, converted into cash based on the spread to the offer price; options with exercise prices above $58.00 were cancelled for no consideration. Gray also disposed of 4,956 common shares pursuant to the tender offer.
RAPT Therapeutics director Michael F. Giordano reported the disposition of equity awards and shares in connection with the company’s acquisition by GlaxoSmithKline. The filing shows multiple Director Stock Options and 4,956 shares of common stock disposed on March 3, 2026, including a disposition pursuant to a tender offer.
Under a Merger Agreement dated January 19, 2026, a GSK subsidiary completed a tender offer to acquire all outstanding RAPT shares for $58.00 per share in cash, followed by a merger that made RAPT an indirect wholly owned subsidiary. At the merger’s effective time, all outstanding RSUs were cancelled and converted into cash based on the Offer Price, and stock options were accelerated; in-the-money options were cashed out using the Offer Price while out-of-the-money options were cancelled without consideration.
RAPT Therapeutics director Ashley L. Dombkowski reported disposing of equity awards in connection with the company’s acquisition by a GlaxoSmithKline affiliate. On March 3, 2026, 25,000 director stock options and 4,956 shares of common stock were surrendered to the issuer or purchaser as part of the closing.
Under a previously signed Merger Agreement, a GlaxoSmithKline subsidiary completed a tender offer to acquire all RAPT common shares for $58.00 per share in cash, then merged with RAPT, which became an indirect wholly owned subsidiary. At the merger’s effective time, all outstanding RSUs and eligible stock options were cancelled and converted into the right to receive cash based on the $58.00 offer price.
RAPT Therapeutics’ chief financial officer, Rodney KB Young, reported the cash-out of equity awards tied to the company’s acquisition by GlaxoSmithKline. The filing shows dispositions of several employee stock options back to the issuer and the tender of 3,304 common shares.
Under a merger agreement with GlaxoSmithKline LLC and its affiliates, all RAPT common shares were acquired for $58.00 per share in cash. Stock options with exercise prices below this offer price were accelerated, then cancelled in exchange for cash equal to their in-the-money value.
Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of the GSK parent. These converted awards retain the original vesting conditions but pay out 50% at closing and 50% nine months later, with full acceleration if the holder is involuntarily terminated within that nine-month period.
RAPT Therapeutics chief scientific officer Dirk G. Brockstedt reported dispositions of common stock and employee stock options tied to the company’s acquisition by a GlaxoSmithKline subsidiary. All transactions occurred on March 3, 2026, when Redrose Acquisition Co. merged with RAPT.
Under a January 19, 2026 Merger Agreement, a tender offer acquired all RAPT common shares at $58.00 per share in cash. At the merger’s effective time, each share of common stock held by the reporting person was exchanged for the cash offer price. All outstanding stock options became fully vested immediately before closing.
In-the-money options were cancelled and converted into a right to receive cash equal to the number of option shares multiplied by the excess of the $58.00 offer price over the applicable exercise price, while out-of-the-money options were cancelled for no consideration. Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of GlaxoSmithKline LLC, preserving prior vesting terms.
Wong Brian Russell reported disposition transactions in this Form 4 filing.
RAPT Therapeutics President and CEO Brian Russell Wong reported multiple equity disposals tied to the company’s sale to GlaxoSmithKline. On March 3, 2026, his common shares were tendered for $58.00 per share in cash under a completed tender offer and merger.
Employee stock options were adjusted for a prior 1-for-8 reverse stock split and, at the merger’s effective time, became fully vested. Options with exercise prices below $58.00 were cancelled and converted into rights to receive cash based on the spread between the offer price and each option’s exercise price.
Certain unvested options granted after March 1, 2025 were instead converted into cash-based awards of the acquirer, with payments scheduled 50% at closing and 50% nine months later, subject to continued service and accelerated payout upon qualifying involuntary termination.
RAPT Therapeutics director Linda Kozick reported the disposition of stock options and common shares in connection with the company’s acquisition by a GlaxoSmithKline affiliate. Multiple “Director Stock Option (right to buy)” awards were disposed of to the issuer on March 3, 2026, leaving no options reported as outstanding afterward.
Under a January 19, 2026 Merger Agreement, a GSK subsidiary completed a tender offer for all RAPT shares at $58.00 per share in cash and then merged into RAPT. The filing notes that RSUs and stock options were cancelled at the merger effective time and converted into cash based on the offer price where in-the-money, while out-of-the-money options were cancelled without payment. The Form 4 also shows a tender-offer disposition of 4,956 shares of common stock for cash consideration at the offer price.
RAPT Therapeutics director Scott Braunstein reported dispositions of equity tied to the company’s merger with a GlaxoSmithKline affiliate. He surrendered 25,000 director stock options back to the issuer and disposed of 4,956 common shares through a tender offer at $58.00 per share.
The filing explains that, under the Merger Agreement, outstanding restricted stock units and stock options were cancelled at the merger’s effective time and converted into cash based on the $58.00 offer price. These transactions reflect automatic treatment of director awards in connection with RAPT becoming an indirect wholly owned subsidiary of GlaxoSmithKline LLC.
RAPT Therapeutics reported an equity grant to director Scott Braunstein. On 01/30/2026, he received 4,956 shares of common stock at a price of $0 per share as a stock-based award, leaving him with 4,956 shares beneficially owned directly.
The award represents the annual grant of restricted stock units (RSUs) under RAPT’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting.
RAPT Therapeutics director Michael F. Giordano reported a stock-based compensation grant. On 01/30/2026 he received 4,956 shares of common stock at a price of $0, reported as directly owned after the transaction.
The footnote explains this represents the annual grant of restricted stock units under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs fully vest on the first anniversary of the grant date, and each unit will deliver one share of common stock upon vesting.
RAPT Therapeutics director Mary Ann Gray received an annual equity grant. On 01/30/2026 she was awarded 4,956 shares of common stock at a grant price of $0, reported as stock under the company’s non-employee director compensation policy.
The award represents 4,956 restricted stock units that fully vest on the first anniversary of the grant date. Each RSU converts into one share of RAPT Therapeutics common stock upon vesting, aligning director compensation with shareholder equity performance.
RAPT Therapeutics director Lori Lyons-Williams reported an annual equity award in the form of restricted stock units. On January 30, 2026, she was granted 4,956 RSUs of RAPT Therapeutics common stock at a price of $0 per unit under the company’s Amended & Restated Non-Employee Director Compensation Policy. These RSUs will fully vest on the first anniversary of the grant date, with each RSU converting into one share of common stock upon vesting. Following this grant, she beneficially owns 4,956 common shares, held directly.
RAPT Therapeutics director Linda Kozick received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a stated price of $0 per unit under the company’s non-employee director compensation policy.
The RSUs fully vest on the first anniversary of the grant date, and each RSU converts into one share of common stock upon vesting. Following this grant, Kozick beneficially owns 4,956 shares directly through these RSUs.
RAPT Therapeutics director Ashley L. Dombkowski received an annual equity grant in the form of restricted stock units. On 01/30/2026, she was awarded 4,956 RSUs of RAPT common stock at a grant price of $0. These RSUs were issued under RAPT’s Amended & Restated Non-Employee Director Compensation Policy.
The 4,956 RSUs fully vest on the first anniversary of the grant date. Each RSU represents a contingent right to receive one share of RAPT common stock upon vesting, and all 4,956 shares are reported as directly owned following this grant.